In the ever growing Chinese economy, healthcare has taken center stage as more and more of the population now has access to first class physician services. Mindray (MR) has been an integral part of this process through the three product lines it offers its customers. The company makes devices relating to 1) Patient monitoring, 2) Diagnostic lab instruments, and 3) Ultrasound imaging systems.
While the company has only been public on US markets for the last 9 months, It has a long profitable history dating back nearly a decade. New products are a vital part of this business and the company commits 10% of all revenue to research and development of these new ideas. Over the next few years, most of the growth will likely come from its color ultrasound machine which has only recently become available. Demand was so strong for this product upon launching that the company was briefly out of stock. It appears manufacturing has been able to catch up and the company was quickly back to selling the product which accounted for 50% of the sales growth last quarter.
While Mindray operates primarily in the China market, it has begun to diversify into other countries to increase revenue and diversify geographically. It is currently selling products in 120+ countries and has many of its products approved by the US FDA, or the European equivalent. For more developing countries, the company focuses on peddling its patient monitoring and diagnostic instruments, while more developed nations such as the US and many European countries, the company is able to sell its high tech new ultrasound machine with good success.
Looking at analyst expectations over the past year or so, it is easily noted that analysts typically underestimate the company's earnings power and constantly have to adjust future expectations higher. I expect this to continue for the next year or two at least as it appears a bit of conservatism is inherent in this industry. Even if the current consensus is correct, the stock is still not extremely expensive for the growth rate it is achieving. I would expect this growth to be fairly stable as the company is not relying on any one specific economy to drive business growth.
While I currently do not have a position in the company, I would look for a small pullback in the shares to buy stock. This is a disciplined approach that I use to minimize my risk in new positions and hopefully allow me to hold winning stocks longer without getting stopped out. I would not discourage someone from taking a position in this name as I believe the growth prospects are very appealing.
FD: Author does not have position in MR
3 comments:
Hello there,
Thank you for your piece about Mindray Medical, I have been watching this stock for the last few months, and indeed the company prospects look very promising, despite that I have chosen to take a position in China Medical Technologies (CMED) instead since I believe CMED has more compelling valuations, and as strong growth prospects as MR, what is your take on CMED?
Best regards,
Nawar Alsaadi
We have traded CMED with a nice profit over the last couple of years. Unfortunately my associate has done much of the research on this name and I'm not as equipped to answer the question. My overall assumption is that CMED is much more China based while MR is becoming an international player. Also the products are different as CMED develops many treatments while MR is much more involved in the diagnostic and monitoring areas.
Thanks for reading and for your comment!
any chinese large cap internets on radar? i played with Baidu in the 70s-90s since last summer and totally exited in the 140s. SAC Capitals huge inventment was an assurance that 70s to 90s was still buying low. but the key immediate application idea i am drawn to is SINA since last Martin Luther King holiday. then about 3 weeks ago GOOGLE and SINA announced a " broad heavy weight comprehensive partnership deal applying the talents of both companies to the MAX. will SINA now go into Maximum Overdrive? boris b
Post a Comment